GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Onconetix ONCO · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.58

-48.49%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$815,371

FY2019FY2025

Net income

−$14.0m

FY2019FY2025

Free cash flow

−$9.7m

FY2019FY2025

Shareholders' equity

$15.8m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue$815,371$2.5m$58,465————
Gross profit$632,913$1.1m−$1.1m−$6,752−$4,890−$3,056−$573
Research and development$66,133$154,359$1.9m$4.1m$1.3m$524,908$60,174
Operating income−$6.3m−$58.3m−$36.8m−$13.5m−$3.4m−$1.6m−$880,230
Net income−$14.0m−$58.7m−$37.4m−$13.4m−$3.4m−$1.6m−$821,915
Diluted earnings per share-4.28-2,118.81-67.03-854.77-299.77-0.53-0.37

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$24.9m$28.2m$87.5m$26.3m$3.1m$4.8m$6.1m
Cash and short-term investments$5.2m$646,500$4.6m$25.8m$1.9m$4.3m$6.1m
Total liabilities$9.2m$18.6m$86.1m$3.9m$1.6m$78,310$82,621
Debt$48,774$9.4m$9.9m————
Shareholders' equity$15.8m$9.6m−$5.6m$22.4m$1.4m$4.7m$6.0m
Shares outstanding3m0m1m0m0m3m2m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−$9.7m−$10.5m−$13.6m−$8.7m−$2.0m−$1.7m−$825,126
Capital spending—−$28,471−$55,044−$9,339−$1,924−$11,792−$4,500
Free cash flow−$9.7m−$10.5m−$13.6m−$8.7m−$2.0m−$1.7m−$829,626
Dividends paid−$409,510−$206,404—————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$17,120$21,457$303,596$303,651$106,494$101,630$711,976$406,859
Gross profit$4,303−$1,655$247,684$268,894$70,503$45,832$659,968$105,414
Operating income−$2.9m−$4.2m$5.7m−$8.5m−$2.1m−$8.3m—−$3.5m
Net income−$2.9m−$4.2m$5.7m−$8.8m−$2.4m−$8.5m−$29.4m−$3.8m
Diluted earnings per share-1.28-1.881.73-2.68-0.72-2.60-1,062.76-138.17
Cash from operations−$1.0m−$2.0m−$3.0m−$3.0m−$1.0m−$1.0m—−$1.0m
Total assets$16.4m$14.8m$24.9m$19.7m$19.1m$18.8m$28.2m$61.9m
Cash and short-term investments$5.9m$3.7m$5.2m$836,556$283,515$1.6m—$341,495
Debt$174,813$271,611$24,412$166,422$8.8m$9.0m—$10.1m
Shareholders' equity$13.5m$11.7m$15.8m$3.4m$5.9m$4.5m$9.6m$33.9m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-22.2%31.4%—
Net income1.5%54.4%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin50.5%———
Operating margin-1936.6%———
Net margin-2177.7%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings——-0.1-0.1
Price to sales0.10.085.5—

Share price return

Finished calendar years

2025202420232022
Return-94%-95%-81%-70%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 6 Nov 2026
  • 10-to-1 reverse split · 21 May 2026
  • 5-to-1 reverse split · 25 Mar 2026
  • 85-to-1 reverse split · 13 Jun 2025
  • 40-to-1 reverse split · 24 Sept 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.